Under one in 10 individuals that would benefit from obesity jabs such as Wegovy can access them, states the World Health Organization as it issues its first recommendations on the drugs.
Given in excess of 1,000,000,000 people worldwide now obese, it is calling for increased and just availability to GLP-1 medication.
Per projections, over two billion could be living with obesity by 2030 if no action is taken.
"The latest guidance affirms that obesity is a lifelong illness that can be managed with thorough and continuous support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are significant hurdles to widespread availability to the treatments that can assist patients in reducing considerable body mass, says the organization.
Skinny Jab Supply Crisis
Even under the present most favorable scenario, the manufacturing of such drugs would only suffice for around 100 million people – fewer than 10% of the global need, according to the health organization.
The advice urges governments and firms to expand availability, through strategies like licensing agreements.
A patent on semaglutide – the main ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026.
How Weight-Loss Injections Work
GLP-1 drugs imitate a body's own hormone to delay gastric emptying, reduce hunger and increase the sense of being full so users consume fewer calories.
Patients commonly see weight reduction within a few weeks of commencing the weekly injections.
Evidence points to users may regain a significant portion after a year of halting the medication, because their usual food cravings come back.
Being above a healthy weight raises your chance for contracting medical conditions, including diabetes, heart disease, stroke, and specific cancers.
Obesity impacts people in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, per the WHO.
